Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in …

JJ Cornelissen, WLJ Van Putten, LF Verdonck… - Blood, 2007 - ashpublications.org
Abstract The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for
Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of …

[HTML][HTML] Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid …

JJ Cornelissen, WLJ van Putten, LF Verdonck… - Blood, 2007 - Elsevier
Abstract The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for
Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of …

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in …

JJ Cornelissen, WLJ van Putten, LF Verdonck… - Blood, 2007 - research.rug.nl
Abstract The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for
Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of …

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in …

JJ Cornelissen, WLJ van Putten, LF Verdonck… - Blood, 2007 - sonar.ch
English Abstract The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss
Group for Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated …

[PDF][PDF] Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid …

JJ Cornelissen, WLJ van Putten, LF Verdonck… - BLOOD, 2007 - Citeseer
Allogeneic hematopoietic stem cell transplantation (allo-SCT) following myeloablative
cytoreductive therapy has been established as a notably powerful treatment modality to …

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in …

J Cornelissen, W van Putten, L Verdonck, M Theobald… - Blood, 2007 - repub.eur.nl
The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical
Cancer Research (HOVON-SAKK) collaborative study group evaluated out-come of patients …

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in …

JJ Cornelissen, WLJ van Putten, LF Verdonck… - …, 2007 - pubmed.ncbi.nlm.nih.gov
The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical
Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of patients …

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in …

JJ Cornelissen, WLJ van Putten, LF Verdonck… - Blood, 2007 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The Dutch-Belgian Hemato-Oncology
Cooperative Group and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) …

[PDF][PDF] Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid …

JJ Cornelissen, WLJ van Putten, LF Verdonck… - BLOOD, 2007 - academia.edu
Allogeneic hematopoietic stem cell transplantation (allo-SCT) following myeloablative
cytoreductive therapy has been established as a notably powerful treatment modality to …

[引用][C] Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid …

JJ CORNELISSEN, WLJ VAN PUTTEN… - Blood, 2007 - pascal-francis.inist.fr
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical
sibling stem cell transplantation in first remission acute myeloid leukemia in young and …